MSK Commack.

Commack, New York 11725

8 studies enrolling now · 20 studies all time

What they study most

Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Malignancies, Advanced Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma, Advanced or Metastatic Solid Tumors, Brain Neoplasms, Brain Neoplasms, Primary, Breast Cancer, Breast Neoplasms, Cancer of the Prostate, Carcinoma, Non-Small-Cell Lung

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors — Recruiting now
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer — Recruiting now
• A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer — Recruiting now
• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 — Recruiting now
• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant — Recruiting now
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
• A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) — Running, not enrolling
• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Running, not enrolling
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — Running, not enrolling
• A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers — Stopped early
• Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing — Running, not enrolling
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Running, not enrolling
• A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. — Running, not enrolling
• A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment — Completed
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement — Stopped early
• A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma — Stopped early
• Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma — NO_LONGER_AVAILABLE